Screener
Travere Therapeutics, Inc. TVTX Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $117.74M+56.7% | $78.36M+26.6% | $93.04M+58.9% | $110.93M+205% | $75.15M+133% | ||
| $175.91M— | $130.59M— | $145.38M— | $138.66M-36.7% | —— | ||
| $80.64M+108% | $87.3M+154% | $80.13M+196% | $82.98M+230% | $38.72M+58.3% | ||
| $32.21M-4.1% | $30.7M-9.9% | $30.28M-15.1% | $32M-12.4% | $33.59M-9.2% | ||
| $615.14M+62.1% | $392.68M+4.9% | $437.57M+5.0% | $371.11M+14.3% | $379.57M+2.9% | ||
| $3.23M-29.2% | $3.63M-25.3% | $4.02M-24.6% | $4.32M-29.9% | $4.56M-30.7% | ||
| $131.52M+24.5% | $110.04M+6.0% | $113.87M+9.5% | $109.44M+5.0% | $105.61M+0.4% | ||
| $799.36M+43.9% | $555.19M+1.2% | $605.19M+1.9% | $538.58M+6.8% | $555.31M+0.8% | ||
| $7.5M-60.8% | $12.91M-16.0% | $24.8M+5.4% | $18.23M-21.4% | $19.13M-26.0% | ||
| $152.03M-19.8% | $125.44M-31.3% | $159.9M-20.3% | $135.07M-28.9% | $189.54M+56.3% | ||
| $774.84M+48.3% | $456.46M-11.5% | $490.36M-8.4% | $465.02M-13.1% | $522.56M-2.5% | ||
| $9K0.0% | $9K0.0% | $9K0.0% | $9K+12.5% | $9K+12.5% | ||
| -$1.54B-2.9% | -$1.51B-1.4% | -$1.47B-1.8% | -$1.48B-6.4% | -$1.5B-12.7% | ||
| $24.52M-25.1% | $98.73M+201% | $114.83M+94.4% | $73.56M+342% | $32.75M+116% | ||
| $799.36M+43.9% | $555.19M+1.2% | $605.19M+1.9% | $538.58M+6.8% | $555.31M+0.8% |
FAQ
- What are Travere Therapeutics, Inc.'s total assets?
- Travere Therapeutics, Inc. (TVTX) holds $799.4M in total assets, up 44.0% year over year.
- How much debt does Travere Therapeutics, Inc. have?
- Travere Therapeutics, Inc. carries $14.1M in total debt against $24.5M of shareholders' equity, a debt-to-equity ratio of 0.58.
- How much cash does Travere Therapeutics, Inc. have?
- Travere Therapeutics, Inc. holds $117.7M in cash and equivalents.
- Can Travere Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 4.05 — current assets exceed current liabilities.
- Where does Travere Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
